Posted by Michael Wonder on 13 Mar 2026
GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk
13 March 2026 - GSK today announced that the US FDA has expanded the approved age indication of Arexvy (respiratory syncytial virus vaccine, [adjuvanted]) to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by the respiratory syncytial virus.
The FDA’s decision was supported by data from a Phase 3b trial demonstrating a non-inferior immune response compared to adults aged 60 years and above.
